^
CANCER:

Mucosal Melanoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
CDK4 amplification
Mucosal Melanoma
dalpiciclib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Mucosal Melanoma
toripalimab
Sensitive
:
B
No biomarker
Mucosal Melanoma
ALKS 4230
Sensitive
:
B
BRAF mutation
Mucosal Melanoma
PD1 inhibitor
Sensitive
:
C3
KIT mutation
Mucosal Melanoma
PD1 inhibitor
Sensitive
:
C3
MDM2 amplification
Mucosal Melanoma
ipilimumab
Resistant
:
C3
MDM4 amplification
Mucosal Melanoma
ipilimumab
Resistant
:
C3
MDM2 amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant
:
C3
MDM2 amplification
Mucosal Melanoma
nivolumab
Resistant
:
C3
MDM4 amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant
:
C3
MDM4 amplification
Mucosal Melanoma
nivolumab
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
ipilimumab
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
nivolumab
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
pembrolizumab
Resistant
:
C3
MDM4 amplification
Mucosal Melanoma
pembrolizumab
Resistant
:
C3
MDM2 amplification
Mucosal Melanoma
pembrolizumab
Resistant
:
C3
NRAS mutation
Mucosal Melanoma
PD1 inhibitor
Resistant
:
C3
BRAF mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive
:
C3
NRAS mutation
Mucosal Melanoma
cisplatin + temozolomide
Sensitive
:
C3
KIT mutation
Mucosal Melanoma
temozolomide
Sensitive
:
C3
BRAF mutation
Mucosal Melanoma
cisplatin + temozolomide
Sensitive
:
C3
NRAS mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive
:
C3
KIT mutation
Mucosal Melanoma
cisplatin + dacarbazine
Sensitive
:
C3
PD-L1 expression
Mucosal Melanoma
toripalimab
Sensitive
:
C3
KIT exon 17 mutation
Mucosal Melanoma
avapritinib
Sensitive
:
C3
KIT L576P
Mucosal Melanoma
sorafenib
Resistant
:
C4
KIT L576P
Mucosal Melanoma
temsirolimus
Resistant
:
C4
KIT L576P
Mucosal Melanoma
imatinib
Resistant
:
C4